On May 21, BioMarin Pharmaceuticals announced positive results from its Phase 3 CANOPY-HCH-3 study for the dwarfism treatment VOXZOGO. These results led to a significant surge in the company's stock price, reflecting investor optimism about the potential effectiveness of the treatment.
